Saturday, November 1, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Barrick Gold Exits Canadian Operations with Major Mine Divestiture

Robert Sasse by Robert Sasse
September 15, 2025
in Commodities, Gold & Precious Metals, Mergers & Acquisitions
0
Barrick Gold Stock
0
SHARES
72
VIEWS
Share on FacebookShare on Twitter

Barrick Gold has initiated a significant strategic pivot, announcing the sale of its Hemlo mine in Ontario for a total potential consideration of $1.09 billion. This transaction effectively concludes the Canadian mining giant’s era as a domestic operator within its home country.

The company has entered into a definitive agreement to divest the asset to Carcetti Capital Corp., which will be renamed Hemlo Mining Corp. upon the deal’s closure. This move is a direct execution of Barrick’s stated strategy to concentrate its portfolio on world-class “Tier One” gold and copper holdings.

Transaction Structure and Strategic Rationale

The financial terms of the sale are structured to provide both immediate and future value for Barrick. The package includes:
* An upfront cash payment of $875 million payable at closing
* An additional $50 million in shares of the newly renamed acquiring company
* Contingent payments of up to $165 million, which are linked to the mine’s future gold production and the performance of gold prices

Barrick’s President and CEO, Mark Bristow, characterized the sale as the closing of a long chapter for the company, noting it was achieved at an attractive valuation. The Hemlo operation has been in continuous production for over three decades. In 2024, it yielded 143,000 ounces of gold, accounting for approximately 3.5% of Barrick’s total output.

Capital Allocation and Portfolio Streamlining

Should investors sell immediately? Or is it worth buying Barrick Gold?

Proceeds from the divestiture are earmarked to further fortify Barrick’s balance sheet and will support its capital allocation framework, a key component of which is returning value to shareholders. This sale is the latest in a series of disciplined moves to divest non-core assets.

When combined with the earlier dispositions of its interests in the Donlin and Alturas projects, Barrick’s gross proceeds from such non-core sales are projected to surpass $2 billion by 2025.

Future Direction: A Shift in Geographic Focus

With the sale of its last remaining operated mine in Canada, Barrick is poised to sharpen its focus on large-scale international growth projects. This strategic direction is expected to include a heightened emphasis on major copper developments, such as the massive Reko Diq project in Pakistan.

This trajectory aligns with the corporation’s long-term vision to significantly boost its production in gold equivalent ounces by the end of this decade. Market observers will now monitor for the successful completion of the Hemlo transaction, anticipated in the fourth quarter, and any subsequent announcements regarding the deployment of the newly raised capital.

Ad

Barrick Gold Stock: Buy or Sell?! New Barrick Gold Analysis from November 1 delivers the answer:

The latest Barrick Gold figures speak for themselves: Urgent action needed for Barrick Gold investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 1.

Barrick Gold: Buy or sell? Read more here...

Tags: Barrick Gold
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Mosaic Stock
Analysis

Mosaic Shares Under Pressure Ahead of Q3 Earnings Release

November 1, 2025
Terex Stock
Earnings

Terex Shares Plunge Amid Major Strategic Overhaul

November 1, 2025
Tetra Stock
Analysis

Tetra Stock Positioned for Significant Gains as Analysts Boost Outlook

November 1, 2025
Next Post
Super Micro Computer Stock

Super Micro Stock Surges on Key AI Chip Deployment Milestone

Anglo American Stock

Anglo American and Teck Forge Landmark Partnership to Reshape Critical Minerals Sector

Intellia Therapeutics Stock

A Turning Point for Intellia Therapeutics: Clinical Progress and Investor Confidence Build Momentum

Recommended

Montrose Environmental Stock

Montrose Environmental: An Under-the-Radar Contender in Green Infrastructure

2 months ago
Applied Optoelectronics Stock

Institutional Vote of Confidence Meets Analyst Skepticism at Applied Optoelectronics

2 months ago
Finance_Fiscal (3)

Title The Bear Cave Report Warning Signs for a Favored ARK Invest Pick

2 years ago
Envela Stock

Envela Shares Present Buying Opportunity Amidst Market Pause

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Univest of Pennsylvania Stock Surges on Impressive Quarterly Performance

Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release

Monster Beverage Faces Critical Q3 Earnings Test

Entravision Communications: A Stock at a Critical Juncture

Mosaic Shares Under Pressure Ahead of Q3 Earnings Release

Richardson Electronics Shares Surge on Stellar Quarterly Performance

Trending

Pulmonx Corp Stock
Earnings

Pulmonx Shares Surge on Leadership Shakeup and Upbeat Forecast

by Andreas Sommer
November 1, 2025
0

Pulmonx Corp witnessed a dramatic single-day rally, with its stock price soaring more than 26% following significant...

Capital Southwest Stock

A Critical Juncture for Capital Southwest Investors

November 1, 2025
Middlesex Water Stock

Can Middlesex Water Maintain Its Dividend Streak Amid Operational Headwinds?

November 1, 2025
Univest of Pennsylvania Stock

Univest of Pennsylvania Stock Surges on Impressive Quarterly Performance

November 1, 2025
Stoke Therapeutics Stock

Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release

November 1, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pulmonx Shares Surge on Leadership Shakeup and Upbeat Forecast
  • A Critical Juncture for Capital Southwest Investors
  • Can Middlesex Water Maintain Its Dividend Streak Amid Operational Headwinds?

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com